AU2018354295B2 - ALK7 binding proteins and uses thereof - Google Patents

ALK7 binding proteins and uses thereof

Info

Publication number
AU2018354295B2
AU2018354295B2 AU2018354295A AU2018354295A AU2018354295B2 AU 2018354295 B2 AU2018354295 B2 AU 2018354295B2 AU 2018354295 A AU2018354295 A AU 2018354295A AU 2018354295 A AU2018354295 A AU 2018354295A AU 2018354295 B2 AU2018354295 B2 AU 2018354295B2
Authority
AU
Australia
Prior art keywords
seq
alk7
amino acid
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018354295A
Other languages
English (en)
Other versions
AU2018354295A1 (en
Inventor
Jonathan Belk
Reselyne CASTONGUAY
Ravindra Kumar
Dianne Sako
Nathan J. Sharkey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2018354295A1 publication Critical patent/AU2018354295A1/en
Assigned to ACCELERON PHARMA INC. reassignment ACCELERON PHARMA INC. Request for Assignment Assignors: ACCELERON PHARMA INC., ADIMAB, LLC
Application granted granted Critical
Publication of AU2018354295B2 publication Critical patent/AU2018354295B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018354295A 2017-10-25 2018-10-25 ALK7 binding proteins and uses thereof Active AU2018354295B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577038P 2017-10-25 2017-10-25
US62/577,038 2017-10-25
PCT/US2018/057482 WO2019084249A1 (en) 2017-10-25 2018-10-25 ALK7 BINDING PROTEINS AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2018354295A1 AU2018354295A1 (en) 2020-04-30
AU2018354295B2 true AU2018354295B2 (en) 2025-08-14

Family

ID=66246796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018354295A Active AU2018354295B2 (en) 2017-10-25 2018-10-25 ALK7 binding proteins and uses thereof

Country Status (9)

Country Link
US (2) US11981738B2 (enExample)
EP (1) EP3700571A4 (enExample)
JP (2) JP7433222B2 (enExample)
KR (1) KR20200089666A (enExample)
CN (1) CN111836642A (enExample)
AU (1) AU2018354295B2 (enExample)
BR (1) BR112020007751A2 (enExample)
CA (1) CA3079963A1 (enExample)
WO (1) WO2019084249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405278B1 (ko) 2016-04-22 2022-06-07 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이들의 용도
EP3700571A4 (en) 2017-10-25 2021-07-28 Acceleron Pharma Inc. ALK7-BINDING PROTEINS AND USES THEREOF
KR20220016136A (ko) * 2019-05-30 2022-02-08 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이의 용도
JP7541709B2 (ja) * 2020-03-19 2024-08-29 株式会社CUBICStars タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185037A1 (en) * 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
AU745965B2 (en) 1997-06-06 2002-04-11 Asat Ag Applied Science & Technology Anti-GPIIb/IIIa recombinant antibodies
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
US8445637B2 (en) 2008-12-05 2013-05-21 Abraxis Bioscience, Llc SPARC binding peptides and uses thereof
JP2017505758A (ja) 2013-12-19 2017-02-23 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のｌｕｋｇｈ（ｌｕｋａｂ）毒素に対する抗体及び抗体配列
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Ｒｎａ에 특이적으로 결합하는 항체
WO2017177013A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3700571A4 (en) 2017-10-25 2021-07-28 Acceleron Pharma Inc. ALK7-BINDING PROTEINS AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185037A1 (en) * 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof

Also Published As

Publication number Publication date
AU2018354295A1 (en) 2020-04-30
US20200392233A1 (en) 2020-12-17
EP3700571A1 (en) 2020-09-02
JP2021500895A (ja) 2021-01-14
JP7433222B2 (ja) 2024-02-19
BR112020007751A2 (pt) 2020-10-20
EP3700571A4 (en) 2021-07-28
WO2019084249A1 (en) 2019-05-02
JP2024023278A (ja) 2024-02-21
US20240287196A1 (en) 2024-08-29
US11981738B2 (en) 2024-05-14
KR20200089666A (ko) 2020-07-27
CA3079963A1 (en) 2019-05-02
CN111836642A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
US11708414B2 (en) ALK7 binding proteins and uses thereof
US20240287196A1 (en) ALK7 Binding Proteins and Uses Thereof
KR102084806B1 (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
KR101453462B1 (ko) Her2에 특이적으로 결합하는 항체
US12365736B2 (en) ALK7 binding proteins and uses thereof
KR20170012754A (ko) Egfr에 특이적으로 결합하는 항체
CN116217731B (zh) Alk7结合蛋白及其用途
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ACCELERON PHARMA INC.

Free format text: FORMER APPLICANT(S): ACCELERON PHARMA INC.; ADIMAB, LLC

FGA Letters patent sealed or granted (standard patent)